Articles by Adeline Siew, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Adeline Siew, PhD

Ethyl cellulose aqueous dispersion: a coating system for oral sustained-release dosage forms

Formulation and process considerations for ethyl cellulose aqueous dispersion in sustained-release applications.
Oct 7, 2013

Formulation and process considerations for ethyl cellulose aqueous dispersion in sustained-release applications.

Elucidating Biosimilars Characterization

Industry experts discuss the importance of characterization studies during biosimilars development and related analytical methods.
Oct 2, 2013

Industry experts discuss the importance of characterization studies during biosimilars development and related analytical methods.

Evaluating Strategies for Oral Absorption Enhancement

Formulation scientists tackle the challenges of improving drug absorption across the gastrointestinal membrane.
Oct 2, 2013

Scientists from the CDMO Metrics talk about the challenges in developing oral formulations for poorly permeable drugs and the strategies used to enhance oral absorption in the gastrointestinal tract.

Novel Solvent-Free Method to Manufacture Metastable Drug Forms

Researchers from the University of Bradford, UK, have developed a solvent-free, continuous method to manufacture the more soluble and bioavailable form of artemisinin. The metastable form produced using high-temperature extrusion has been shown to have greater stability and longer shelf-life.
Sep 30, 2013

Researchers from the University of Bradford, UK, have developed a solvent-free, continuous method to manufacture the more soluble and bioavailable form of artemisinin. The metastable form produced using high-temperature extrusion has been shown to have greater stability and longer shelf-life.

Novartis' MS Drug Gilenya Under FDA Investigation for PML Case

FDA has issued a safety alert after a patient with multiple sclerosis (MS) in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy (PML) following treatment with Gilenya (fingolimod).
Sep 2, 2013

FDA has issued a safety alert after a patient with multiple sclerosis in Europe developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy following treatment with Gilenya (fingolimod).

Gauging the Outlook of the Biologics Market

A Q&A with Mike Jenkins, Catalent
Sep 2, 2013

Mike Jenkins, general manager of Catalent Biologics discusses the evolving landscape of the biologics market and hurdles faced in the development and manufacture of these innovative products.

Roche's Timesaving Formulation for Breast Cancer Drug Approved in Europe

The new subcutaneous formulation of Herceptin can be administered six times faster than the standard intravenous formulation.
Sep 2, 2013

The new subcutaneous formulation of Herceptin can be administered six times faster than the standard intravenous formulation.

The Importance of Characterization in Biosimilars Development

Industry experts discuss the requirements and challenges involved in getting a biosimilar product from bench to launch.
Sep 2, 2013

Industry experts discuss the requirements and challenges involved in getting a biosimilar product from bench to launch.

MHRA Warns of Dangerous Traditional Chinese Medicines

The MHRA has issued a warning to the public not to use unlicensed traditional Chinese medicines after discovering that some of them contain dangerously high levels of lead, mercury and arsenic.
Aug 22, 2013

The MHRA has issued a warning to the public not to use unlicensed traditional Chinese medicines after discovering that some of them contain dangerously high levels of lead, mercury and arsenic.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here